Page last updated: 2024-10-24

busulfan and Ewing Sarcoma

busulfan has been researched along with Ewing Sarcoma in 29 studies

Research Excerpts

ExcerptRelevanceReference
"Ewing 2008R3 was conducted in 12 countries and evaluated the effect of treosulfan and melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfusion of autologous hematopoietic stem cells on event-free survival (EFS) and overall survival in high-risk Ewing sarcoma (EWS)."9.51High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma. ( Bauer, S; Baumhoer, D; Bernkopf, M; Bhadri, V; Bonar, F; Bovee, J; Brichard, B; Burdach, S; Butterfaß-Bahloul, T; Collaud, S; Cyprova, S; Dhooge, C; Dirksen, U; Egerer, G; Eich, HT; Ek, T; Faldum, A; Gelderblom, H; Hardes, J; Hartmann, W; Hassenpflug, W; Hauser, P; Haveman, L; Hjorth, L; Hong, A; Jürgens, H; Kanerva, J; Kessler, T; Kiss, J; Koch, R; Kruseova, J; Kühne, T; Metzler, M; Paulussen, M; Raciborska, A; Ranft, A; Rascon, J; Reichardt, P; Renard, M; Timmermann, B; van den Berg, H; Vieth, V, 2022)
"We report a prospective Phase II study of efficacy and toxicity for oral treosulfan in advanced Ewing sarcoma."9.20A phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre-treated Ewing sarcoma ISRCTN11631773. ( Forsyth, S; Michelagnoli, M; Whelan, J, 2015)
"This mono-institutional observational study was conducted to determine incidence, severity, risk factors, and outcome of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in high-risk Ewing sarcoma (ES) patients treated with intravenous busulfan and melphalan (BU-MEL) followed by autologous stem cell transplantation (ASCT)."7.88Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma. ( Abate, ME; Cammelli, S; Carretta, E; Cesari, M; Ferrari, S; Longhi, A; Paioli, A; Palmerini, E; Picci, P; Piscaglia, F, 2018)
"A Ewing sarcoma grown in immunosuppressed mice was eradicated with a single lethal dose of dimethylmyleran (DMM) followed by autologous or syngeneic bone marrow."7.66Control of a human tumour (Ewing sarcoma) in mice by a single lethal dose of dimethyl-myleran and bone marrow. ( Floersheim, GL; Torhorst, J, 1981)
"Ewing 2008R3 was conducted in 12 countries and evaluated the effect of treosulfan and melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfusion of autologous hematopoietic stem cells on event-free survival (EFS) and overall survival in high-risk Ewing sarcoma (EWS)."5.51High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma. ( Bauer, S; Baumhoer, D; Bernkopf, M; Bhadri, V; Bonar, F; Bovee, J; Brichard, B; Burdach, S; Butterfaß-Bahloul, T; Collaud, S; Cyprova, S; Dhooge, C; Dirksen, U; Egerer, G; Eich, HT; Ek, T; Faldum, A; Gelderblom, H; Hardes, J; Hartmann, W; Hassenpflug, W; Hauser, P; Haveman, L; Hjorth, L; Hong, A; Jürgens, H; Kanerva, J; Kessler, T; Kiss, J; Koch, R; Kruseova, J; Kühne, T; Metzler, M; Paulussen, M; Raciborska, A; Ranft, A; Rascon, J; Reichardt, P; Renard, M; Timmermann, B; van den Berg, H; Vieth, V, 2022)
"Dose-intensive chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide is more effective, less toxic, and shorter in duration for all stages of newly diagnosed Ewing sarcoma than vincristine, ifosfamide, doxorubicin, and etoposide induction and should now be the standard of care for Ewing sarcoma."5.51Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial. ( Brennan, B; Fenwick, N; Gaspar, N; Gelderblom, H; Kirton, L; Laurence, V; Marec-Bérard, P; Martín-Broto, J; Moroz, V; Owens, C; Sastre, A; Strauss, S; Wheatley, K; Whelan, J, 2022)
"Radiation myelopathy is a rare, devastating, late effect of radiotherapy to the spinal cord."5.33Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice. ( Cassoni, AM; Galloway, MJ; Rees, JH; Seddon, BM; Whelan, JS, 2005)
"We report a prospective Phase II study of efficacy and toxicity for oral treosulfan in advanced Ewing sarcoma."5.20A phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre-treated Ewing sarcoma ISRCTN11631773. ( Forsyth, S; Michelagnoli, M; Whelan, J, 2015)
"Patients aged ≤40 years with nonmetastatic Ewing sarcoma (ES) received vincristine (V), doxorubicin (A), cyclofosfamide (C), actinomycin (Ac), ifosfamide (I) and etoposide (E) (VACAc-IE regimen) as induction chemotherapy."5.15Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol. ( Alberghini, M; Alvegard, TA; Bacci, G; Barbieri, E; Brach Del Prever, A; Capanna, R; Carli, M; Fagioli, F; Ferrari, S; Gandola, L; Luksch, R; Mapelli, S; Mercuri, M; Picci, P; Prete, A; Smeland, S; Sundby Hall, K; Tamburini, A; Tienghi, A; Wiebe, T, 2011)
"To improve the prognosis for patients with metastatic Ewing sarcoma/primitive neuroectodermal tumors (ES/PNET) using conventional chemotherapy and consolidation high-dose chemotherapy (HDCT) containing busulfan and melphalan."5.12Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant. ( Desfachelles, AS; Lejars, O; Michon, J; Oberlin, O; Philip, T; Plantaz, D; Plouvier, E; Rey, A; Rubie, H; Schmitt, C; Terrier, P, 2006)
"This mono-institutional observational study was conducted to determine incidence, severity, risk factors, and outcome of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in high-risk Ewing sarcoma (ES) patients treated with intravenous busulfan and melphalan (BU-MEL) followed by autologous stem cell transplantation (ASCT)."3.88Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma. ( Abate, ME; Cammelli, S; Carretta, E; Cesari, M; Ferrari, S; Longhi, A; Paioli, A; Palmerini, E; Picci, P; Piscaglia, F, 2018)
"Post-relapse survival (PRS) was evaluated in patients with Ewing sarcoma (EWS) enrolled in chemotherapy protocols based on the use of high-dose chemotherapy with busulfan and melfalan (HDT) as a first-line consolidation treatment in high-risk patients."3.81Post-relapse survival in patients with Ewing sarcoma. ( Abate, ME; Brach del Prever, A; Cammelli, S; DiGirolamo, S; Eriksson, M; Fagioli, F; Ferrari, S; Hall, KS; Luksch, R; Paioli, A; Podda, M; Prete, A; Tamburini, A; Tienghi, A, 2015)
"To evaluate the potential of diffusion-weighted imaging (DWI) for monitoring dose-dependent tumor response in a mouse-xenograft model of Ewing sarcoma after administration of treosulfan in different dosages."3.75Diffusion-weighted imaging as predictor of therapy response in an animal model of Ewing sarcoma. ( Elverfeldt, DV; Juettner, E; Kontny, U; Reichardt, W; Uhl, M, 2009)
" As little data are available about the in-vitro toxicity of busulfan and treosulfan especially on pediatric tumor cell lines, we compared the cytotoxicity of treosulfan and busulfan on four Ewing tumor, four neuroblastoma, two osteosarcoma and two leukemia cell lines in vitro."3.73Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines. ( Boos, J; Bremer, A; Dirksen, U; Jürgens, H; Lanvers-Kaminsky, C, 2006)
"A Ewing sarcoma grown in immunosuppressed mice was eradicated with a single lethal dose of dimethylmyleran (DMM) followed by autologous or syngeneic bone marrow."3.66Control of a human tumour (Ewing sarcoma) in mice by a single lethal dose of dimethyl-myleran and bone marrow. ( Floersheim, GL; Torhorst, J, 1981)
" Whenever one patient at one dosage level showed a grade III or grade IV reversible toxicity, additional patients were admitted (one by one) up to a maximum number of 6."2.69Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors. ( Bella, S; Burnelli, R; Garaventa, A; Locatelli, F; Melchionda, F; Paolucci, G; Pession, A; Prete, A, 1999)
"Radiation myelopathy is a rare, devastating, late effect of radiotherapy to the spinal cord."1.33Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice. ( Cassoni, AM; Galloway, MJ; Rees, JH; Seddon, BM; Whelan, JS, 2005)
"Eighteen patients with poor risk Ewing's sarcoma (including 11 patients with metastatic disease at presentation) received consolidation therapy of busulphan and melphalan with autologous stem cell rescue."1.30High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. ( Ashley, S; Atra, A; Calvagna, V; Pinkerton, CR; Shankar, AG; Shepherd, V; Souhami, RL; Whelan, JS, 1997)

Research

Studies (29)

TimeframeStudies, this research(%)All Research%
pre-19901 (3.45)18.7374
1990's6 (20.69)18.2507
2000's9 (31.03)29.6817
2010's8 (27.59)24.3611
2020's5 (17.24)2.80

Authors

AuthorsStudies
Koch, R1
Gelderblom, H4
Haveman, L1
Brichard, B1
Jürgens, H3
Cyprova, S1
van den Berg, H1
Hassenpflug, W1
Raciborska, A2
Ek, T1
Baumhoer, D1
Egerer, G1
Eich, HT2
Renard, M1
Hauser, P1
Burdach, S1
Bovee, J1
Bonar, F1
Reichardt, P1
Kruseova, J1
Hardes, J1
Kühne, T1
Kessler, T1
Collaud, S1
Bernkopf, M1
Butterfaß-Bahloul, T1
Dhooge, C1
Bauer, S1
Kiss, J1
Paulussen, M1
Hong, A1
Ranft, A2
Timmermann, B1
Rascon, J1
Vieth, V1
Kanerva, J1
Faldum, A1
Metzler, M1
Hartmann, W1
Hjorth, L1
Bhadri, V1
Dirksen, U3
Cohen, IJ1
Ash, S1
Brennan, B3
Kirton, L2
Marec-Bérard, P3
Gaspar, N3
Laurence, V4
Martín-Broto, J3
Sastre, A3
Owens, C3
Fenwick, N3
Strauss, S3
Moroz, V3
Whelan, J4
Wheatley, K3
Anderton, J1
Kaiser, S1
Fernández-Pinto, M1
Evans, A1
Scobioala, S1
Abate, ME3
Paioli, A2
Cammelli, S2
Cesari, M1
Longhi, A1
Palmerini, E1
Ferrari, S4
Carretta, E1
Picci, P3
Piscaglia, F1
Michelagnoli, M1
Forsyth, S1
Luksch, R3
Hall, KS2
Fagioli, F3
Prete, A4
Tamburini, A3
Tienghi, A3
DiGirolamo, S1
Podda, M2
Eriksson, M2
Brach del Prever, A2
Dourthe, ME1
Ternès, N1
Gajda, D1
Paci, A1
Dufour, C1
Benhamou, E1
Valteau-Couanet, D2
Reichardt, W2
Juettner, E1
Uhl, M2
Elverfeldt, DV1
Kontny, U2
Bölling, T1
Ernst, I1
Willich, N1
Diaz, MA2
Lassaletta, A1
Perez, A1
Sevilla, J1
Madero, L2
Gonzalez-Vicent, M1
Sundby Hall, K1
Wiebe, T1
Alvegard, TA1
Alberghini, M1
Gandola, L2
Mercuri, M1
Capanna, R1
Mapelli, S1
Carli, M1
Barbieri, E2
Bacci, G1
Smeland, S2
Drabko, K1
Bilska, K1
Styczynski, J1
Ussowicz, M1
Choma, M1
Wojcik, B1
Zaucha-Prazmo, A1
Gorczynska, E1
Skoczen, S1
Wozniak, W1
Chybicka, A1
Wysocki, M1
Gozdzik, J1
Kowalczyk, J1
Ruggieri, P1
Daolio, P1
Lindholm, P1
Bisogno, G1
Grignani, G1
Pierga, JY1
Barthier, S1
Babinet, A1
Alapetite, C1
Palangié, T1
de Pinieux, G1
Anract, P1
Pouillart, P1
Seddon, BM1
Cassoni, AM1
Galloway, MJ1
Rees, JH1
Whelan, JS3
McTiernan, A1
Driver, D1
Michelagnoli, MP1
Kilby, AM1
Lanvers-Kaminsky, C1
Bremer, A1
Boos, J1
Oberlin, O1
Rey, A1
Desfachelles, AS1
Philip, T1
Plantaz, D1
Schmitt, C1
Plouvier, E1
Lejars, O1
Rubie, H1
Terrier, P1
Michon, J1
Werner, S1
Mendoza, A1
Hilger, RA1
Erlacher, M1
Lissat, A1
Konanz, C1
Niemeyer, CM1
Khanna, C1
Floersheim, GL1
Torhorst, J1
Mitchell, PL1
Shepherd, VB1
Proctor, HM1
Dainton, M1
Cabral, SD1
Pinkerton, CR2
Vassal, G1
Challine, D1
Koscielny, S1
Hartmann, O1
Deroussent, A1
Boland, I1
Lemerle, J1
Lévi, F1
Gouyette, A1
Atra, A1
Calvagna, V1
Shankar, AG1
Ashley, S1
Shepherd, V1
Souhami, RL1
Yonemoto, T1
Tatezaki, S1
Ishii, T1
Satoh, T1
Pession, A1
Locatelli, F1
Bella, S1
Melchionda, F1
Garaventa, A1
Burnelli, R1
Paolucci, G1
Vicent, MG1
Hawkins, D1
Barnett, T1
Bensinger, W1
Gooley, T1
Sanders, J1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma[NCT00987636]Phase 3907 participants (Actual)Interventional2009-10-01Completed
Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse[NCT04758000]Phase 267 participants (Anticipated)Interventional2021-03-01Recruiting
Observational Study on Treatment of Skeletal Ewing Sarcoma at Diagnosis[NCT04845893]100 participants (Anticipated)Observational2021-06-01Recruiting
A Phase I Trial of Busulfan, Thiotepa and Melphalan Followed by Autologous or Syngeneic Peripheral Blood Stem Cell Transplantation and Followed by Total Marrow (Skeletal) Irradiation (TMI) in Patients With High-Risk Ewing's Sarcoma, PNET or Rhabdomyosarco[NCT00003081]Phase 116 participants (Anticipated)Interventional1998-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for busulfan and Ewing Sarcoma

ArticleYear
Risk stratification of pulmonary toxicities in the combination of whole lung irradiation and high-dose chemotherapy for Ewing sarcoma patients with lung metastases: a review.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2020, Volume: 196, Issue:6

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Combined Modality Thera

2020
Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor.
    American journal of clinical oncology, 2005, Volume: 28, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols

2005

Trials

9 trials available for busulfan and Ewing Sarcoma

ArticleYear
High-Dose Treosulfan and Melphalan as Consolidation Therapy Versus Standard Therapy for High-Risk (Metastatic) Ewing Sarcoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 07-20, Volume: 40, Issue:21

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Consolidation Chemother

2022
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
    Lancet (London, England), 2022, 10-29, Volume: 400, Issue:10362

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph

2022
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
    Lancet (London, England), 2022, 10-29, Volume: 400, Issue:10362

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph

2022
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
    Lancet (London, England), 2022, 10-29, Volume: 400, Issue:10362

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph

2022
Comparison of two chemotherapy regimens in patients with newly diagnosed Ewing sarcoma (EE2012): an open-label, randomised, phase 3 trial.
    Lancet (London, England), 2022, 10-29, Volume: 400, Issue:10362

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Bone Neoplasms; Busulfan; Cyclophosph

2022
International randomised controlled trial for the treatment of newly diagnosed EWING sarcoma family of tumours - EURO EWING 2012 Protocol.
    Trials, 2020, Jan-17, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents;

2020
A phase II study to determine the efficacy and safety of oral treosulfan in patients with advanced pre-treated Ewing sarcoma ISRCTN11631773.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:1

    Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Busulfan

2015
Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian Sarcoma Group/Scandinavian Sarcoma Group III protocol.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child;

2011
Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Société Française des Cancers de l'Enfant.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-20, Volume: 24, Issue:24

    Topics: Adolescent; Adult; Analysis of Variance; Antineoplastic Agents, Alkylating; Antineoplastic Combined

2006
Phase I study of high-dose thiotepa with busulfan, etoposide, and autologous stem cell support in children with disseminated solid tumors.
    Medical and pediatric oncology, 1999, Volume: 33, Issue:5

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C

1999
High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors.
    Bone marrow transplantation, 1999, Volume: 24, Issue:11

    Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Agents, Alkylating; Blood Cell Count; Bone Disease

1999
Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
    Medical and pediatric oncology, 2000, Volume: 34, Issue:5

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols

2000

Other Studies

18 other studies available for busulfan and Ewing Sarcoma

ArticleYear
New Approaches Promise to Improve Local Ewing Sarcoma Results.
    Journal of pediatric hematology/oncology, 2022, 08-01, Volume: 44, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Disease-Free Survival; Hum

2022
Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma.
    Bone marrow transplantation, 2018, Volume: 53, Issue:5

    Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantatio

2018
Post-relapse survival in patients with Ewing sarcoma.
    Pediatric blood & cancer, 2015, Volume: 62, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child;

2015
Busulfan-Melphalan followed by autologous stem cell transplantation in patients with high-risk neuroblastoma or Ewing sarcoma: an exposed-unexposed study evaluating the clinical impact of the order of drug administration.
    Bone marrow transplantation, 2016, Volume: 51, Issue:9

    Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantatio

2016
Diffusion-weighted imaging as predictor of therapy response in an animal model of Ewing sarcoma.
    Investigative radiology, 2009, Volume: 44, Issue:5

    Topics: Animals; Antineoplastic Agents, Alkylating; Bone Neoplasms; Busulfan; Cell Line, Tumor; Diffusion Ma

2009
Radiation toxicity following busulfan/melphalan high-dose chemotherapy in the EURO-EWING-99-trial: review of GPOH data.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2009, Volume: 185 Suppl 2

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Chemotherapy,

2009
High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk ewing sarcoma patients: a long-term follow-up single-center study.
    Pediatric hematology and oncology, 2010, Volume: 27, Issue:4

    Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Female; Follow-Up Studies; Humans; Male; Melph

2010
Consolidation of first-line therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma.
    Bone marrow transplantation, 2012, Volume: 47, Issue:12

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child;

2012
Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl

2012
Fatal radiation myelopathy after high-dose busulfan and melphalan chemotherapy and radiotherapy for Ewing's sarcoma: a review of the literature and implications for practice.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2005, Volume: 17, Issue:5

    Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Combined Modal

2005
High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Bone Neoplasms; Busulfa

2006
Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines.
    Anti-cancer drugs, 2006, Volume: 17, Issue:6

    Topics: Antineoplastic Agents, Alkylating; Bone Neoplasms; Busulfan; Cell Survival; Humans; Leukemia; Neurob

2006
Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:1

    Topics: Animals; Annexin A5; Antineoplastic Agents, Alkylating; Apoptosis; Bisbenzimidazole; Blotting, Weste

2008
Control of a human tumour (Ewing sarcoma) in mice by a single lethal dose of dimethyl-myleran and bone marrow.
    International journal of cancer, 1981, Jun-15, Volume: 27, Issue:6

    Topics: Animals; Bone Marrow Transplantation; Busulfan; Dose-Response Relationship, Drug; Humans; Immunosupp

1981
Peripheral blood stem cells used to augment autologous bone marrow transplantation.
    Archives of disease in childhood, 1994, Volume: 70, Issue:3

    Topics: Acute Disease; Adolescent; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy;

1994
Chronopharmacology of high-dose busulfan in children.
    Cancer research, 1993, Apr-01, Volume: 53, Issue:7

    Topics: Bone Marrow Transplantation; Brain Neoplasms; Busulfan; Child; Child, Preschool; Circadian Rhythm; D

1993
High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma.
    Bone marrow transplantation, 1997, Volume: 20, Issue:10

    Topics: Adolescent; Adult; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms;

1997
[High-dose chemotherapy with autologous peripheral blood stem cell transplantation (PBSCT) for refractory bone and soft tissue sarcomas].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:10

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Child;

1999